Synergistic neoadjuvant radioimmunotherapy in locally advanced rectal cancer: mechanisms of pathologic response and the shift toward organ preservation.
The management of locally advanced rectal cancer (LARC) has progressively shifted beyond surgery alone toward integrated protocols that include neoadjuvant chemoradiotherapy (nCRT). Even so, the risks of distant metastasis and organ dysfunction remain significant challenges. It is against this backdrop that immune checkpoint inhibitors (ICIs) combined with chemoradiotherapy have begun to redefine therapeutic possibilities. Radiotherapy (RT) induces immunogenic cell death (ICD), enhances antigen presentation, and activates systemic immune responses, whereas ICIs overcome immune suppression by blocking pathways such as PD-1/PD-L1. This synergistic approach converts immunologically cold tumors into infiltrated, hot phenotypes. Building on this rationale, recent Phase II trials have explored immune consolidation following short-course radiotherapy (SCRT) within a total neoadjuvant therapy (TNT) framework. What emerged was particularly compelling: pathological complete response (pCR) rates rose notably, in some cases doubling historical benchmarks. This improvement is not merely a numerical gain; it translates into tangible clinical opportunities, including organ preservation and the feasibility of watch-and-wait (W&W) protocols for selected responders. Notably, SCRT appears especially compatible with subsequent immunotherapy, perhaps due to its abbreviated yet potent immunomodulatory effects, offering a pragmatic alternative to conventional long-course regimens. Looking ahead, the push toward personalization is gaining momentum. Biomarkers like MMR/MSI status, features of the tumor immune microenvironment, and dynamic changes in ctDNA are increasingly guiding trial design and treatment sequencing. While promising, these tools require further validation in larger, more diverse cohorts. Ultimately, the central question remains: how can we convert higher pCR rates into lasting survival benefits while safeguarding quality of life? Answering this will depend on rigorously designed Phase III trials, thoughtful integration of predictive biomarkers, and continued refinement of how and when we combine radiation, chemotherapy, and immunotherapy. Only then can we ensure that advances in biology translate into meaningful human outcomes.